At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BDRX BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD
Market Closed 04-26 16:00:00 EDT
1.30
+0.58
+79.36%
盘后1.22
-0.08-6.15%
19:59 EDT
High1.74
Low1.14
Vol70.82M
Open1.66
D1 Closing0.7248
Amplitude82.78%
Mkt Cap5.70M
Tradable Cap3.63M
Total Shares4.38M
T/O98.79M
T/O Rate2,537.70%
Tradable Shares2.79M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Sector Update: Health Care Stocks Edge Higher Late Afternoon
BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.